Series A Term Sheet: A Founder's Section-by-Section Guide

The Series A Term Sheet: A Founder's Section-by-Section Guide

The term sheet is the shortest document in your Series A. It is also the one that quietly determines who runs your company for the next decade. Everything the definitive agreements do — the Charter, the Stock Purchase Agreement, the Investors' Rights Agreement, the Voting Agreement, the Right of First Refusal & Co-Sale Agreement — is negotiated in the term sheet first and then papered afterward. If a right is not in the term sheet, you can usually push back when it appears in the drafts. If it is in the term sheet, it is almost always in the deal.

This guide walks through a standard Series A Preferred Stock term sheet the way a founder and their counsel should read it: one block at a time. For each section you will find what the clause is actually doing, the numbers and thresholds that matter, the mistakes founders make when they skim, and the questions to ask before you sign.

Every clean term sheet opens with a paragraph that reads roughly: "This Term Sheet summarizes the principal terms of the Series A Preferred Stock Financing of [Company]. No legally binding obligations will be created until definitive agreements are executed and delivered by all parties. This Term Sheet is not a commitment to invest, and is conditioned on the completion of due diligence, legal review and documentation that is satisfactory to the Investors."

First, the term sheet is non-binding as to the financing itself — the investor is not yet obligated to wire. Second, the term sheet is usually binding as to exclusivity, confidentiality, and expense reimbursement if those clauses are present. Many founders assume the whole document is non-binding and are surprised weeks later when they cannot shop the round to another fund because they signed a 30- or 45-day no-shop. Before you countersign, mark every clause and ask counsel which ones survive termination.

The header also fixes governing law. "This Term Sheet shall be governed in all respects by the laws of [State]" usually matches your state of incorporation — Delaware in most venture deals. If the investor proposes a different state, ask why.

The identity block seems mechanical, but three things matter:

Company should be your exact legal name, matching your Charter. A term sheet that names your product brand instead of the corporation creates title issues at closing.

Securities will almost always read "Series A Preferred Stock." If it reads "Series Seed Preferred" or "Series A-1," you are not raising a clean Series A; you are extending or restructuring, and the rest of the document should be read accordingly.

Investors is defined as "one or more accredited investors approved by the Company." The "approved by the Company" language is not throwaway — it is what lets you refuse a syndicate member you did not want. Do not delete it.

The three numbers investors and founders argue about most are actually one number expressed three ways.

Pre-Money Valuation is the value assigned to the company before the new money.

Price Per Share is the pre-money valuation divided by the fully-diluted share count.

The phrase to circle is "fully-diluted pre-money valuation." "Fully-diluted" means the share count used to calculate the price includes not just outstanding common and preferred, but also all outstanding options, warrants, convertible notes, SAFEs, and — critically — the unissued portion of the option pool. If the term sheet says "the option pool will be increased to [X]% post-Closing" and that increase is included in the pre-money share count, the pool refresh is being funded entirely by the founders' dilution, not the investors'.

Before you sign, ask your counsel to model the pre-money and post-money cap table both ways: with the pool refresh in the pre-money and with it in the post-money. The two scenarios can differ by several points of founder ownership on a $2M pool expansion.

The Capitalization block references the cap table before and after the Closing. In practice this is an exhibit, not a paragraph. The exhibit is where the pool refresh, the SAFE conversions, and any warrant coverage show up in numbers. Reconcile every row against your carta or shareworks report before you send the term sheet back. Discrepancies discovered in diligence delay closings by weeks.

The section labeled "CHARTER" is not describing a separate document to sign at this stage — it is describing what the amended and restated Certificate of Incorporation will say when it is filed at Closing. The Charter is the deepest document in a venture deal because it is public, it survives every subsequent round, and it defines the rights of the Preferred Stock against the Common Stock forever.

"Dividends will be paid on the Series A Preferred on an as-converted basis when, as, and if paid on the Common Stock" is the founder-friendly default. It means dividends are non-cumulative and non-preferential — the Preferred only gets paid if a dividend is declared on the Common, and only in proportion to their converted ownership.

Watch for the alternative language: "cumulative dividends of [8]% per annum, whether or not declared." Cumulative dividends accrue silently every year and are paid on top of the liquidation preference at exit. On a $10M Series A held for seven years, an 8% cumulative dividend adds $5.6M to the preference. This is not a Series A clause in a normal venture round. If it appears, treat it as a red flag.

This is the single most important economic clause in the term sheet after price. A clean, market Series A liquidation preference reads:

"First pay one times the Original Purchase Price plus declared and unpaid dividends on each share of Series A Preferred (or, if greater, the amount that the Series A Preferred would receive on an as-converted basis). The balance of any proceeds shall be distributed pro rata to holders of Common Stock."

1. The preference is 1x, not 2x or 3x. Anything above 1x transfers economics from Common to Preferred on every exit. 2. The preference is non-participating. The Preferred chooses at exit between (a) taking their 1x back off the top and letting the Common share the rest, or (b) converting to Common and taking their pro rata. They do not do both. Participating Preferred takes 1x off the top and shares in the balance, which meaningfully changes exit math for founders on any outcome under about 3x the last round. 3. There is no dividend accrual added to the preference.

The next paragraph — "A merger or consolidation ... will be treated as a Deemed Liquidation Event" — is standard. It ensures the preference is paid on an acquisition, not just a wind-down. The carve-out you want is that a majority of the Preferred can waive Deemed Liquidation treatment, so a strategic exit that the investors are happy with does not have to trigger the preference machinery.

The default is that Preferred votes with Common on an as-converted basis. That is fair. The exception written into the block is the Series A Director: so long as at least [X]% of the Series A remains outstanding, the Preferred as a class elects one board seat.

The percentage threshold that keeps the Series A Director seat alive. If it is set too low (e.g., 5%), the seat effectively survives forever, even after dilution in later rounds. If it is set too high (e.g., 50%), you may lose it prematurely.

Whether the seat is investor-designated or investor-elected. Designated is stronger for the investor; elected requires a class vote and gives the founders room in a future fight.

The final sentence — that authorized Common can be increased or decreased with a combined majority vote and without a separate class vote by the Common — is the founder-friendly formulation. Do not let it flip to require a separate Common class vote; it will bottleneck every option pool refresh.

This block is the list of actions the Company cannot take without the written consent of a majority of the Series A. Read every item:

Liquidation, dissolution, or Deemed Liquidation Event — the investors get a veto over selling the company. This is standard.

Amendments to the Charter or Bylaws adverse to the Series A — standard.

Issuing securities senior to or on parity with the Series A — this is what prevents a hostile Series B from washing them out. Standard.

Redemptions or dividends on other stock — prevents cash from leaving the company to earlier holders. Standard, with the customary carve-out for stock repurchased from departing employees at the lower of fair market value or cost.

Creating debt above a stated threshold — the dollar cap matters. Set it high enough to cover a normal venture debt facility (typically 25–35% of the equity raise); otherwise you will be back at the Series A investors every time you draw on a credit line.

Creating or disposing of non-wholly-owned subsidiaries — standard, but if your business is likely to build joint ventures, negotiate an exception.

Changing the size of the Board — the most under-negotiated line in the block. If this veto exists and you want to add an independent director later, you need the Series A's consent every time.

Every protective provision is a future consent request. Assume each one will be exercised.

Optional Conversion, Conversion Price Adjustments, Mandatory Conversion

Optional Conversion at 1:1, subject to adjustment, is standard. The Preferred can flip to Common any time.

Conversion Price Adjustments — the anti-dilution formula — should read "broad-based weighted-average." That is the founder-friendly market default. "Narrow-based weighted-average" is worse for founders; "full ratchet" is materially worse and should be resisted at the term sheet stage. Ratchet anti-dilution repriced entire Series A rounds to the price of down rounds in 2008 and 2022; do not agree to it lightly.

Mandatory Conversion on a Qualified Public Offering ("QPO") at 3x the Original Purchase Price with a minimum gross proceeds threshold is standard. The alternative trigger — written consent of holders of a majority (or supermajority) of the Series A — is also standard. Watch the supermajority number: 66.7% is common; anything above 75% gives a small minority a blocking right at IPO.

"Standard representations and warranties by the Company" is doing a lot of work. In the actual SPA, this becomes 15–25 pages covering title, capitalization, litigation, IP, employment, taxes, financial statements, material contracts, and compliance. The term sheet's job is to signal that the reps will be "standard" — meaning benchmarked against the NVCA model — and not expanded. If the term sheet adds specific reps beyond "standard," those are the ones counsel should push back on first.

"Satisfactory completion of financial and legal due diligence, qualification under Blue Sky laws, and the filing of the Certificate of Incorporation" is standard. The word "satisfactory" is subjective, which is what makes the term sheet non-binding on the investment. Do not attempt to remove it; instead, control the process by moving diligence forward in parallel with drafting.

The clean version is: "The Company and the Investors will each bear their own legal and other expenses." The more common venture version is that the Company reimburses the lead investor's legal fees up to a cap ($30,000–$75,000 for a typical Series A). Negotiate the cap; the difference between $40k and $100k in reimbursed legal fees will be paid out of your closing wire.

"Piggyback and demand registration rights that are customary" — market. The mechanics live in the IRA. The two numbers to check in drafting are the number of demand registrations (typically two) and the minimum offering size that triggers a demand (typically several times the round size).

Standard information rights entitle any Major Investor — defined by a dollar threshold of Series A purchased — to (i) audited annual, quarterly, and monthly financials, (ii) an annual operating budget delivered 30 days before the fiscal year, and (iii) an updated capitalization table each quarter.

The dollar threshold for "Major Investor" is the negotiation. Set it high enough that only the lead and co-lead qualify. Every investor who qualifies is someone you send monthly financials to and who has facility-inspection rights. Twenty Major Investors is an administrative burden; three is manageable.

The competitor carve-out — "Any Major Investor (who is not a competitor)" — is standard. Insist on it.

The pro rata right lets Major Investors participate in future rounds in proportion to their ownership. Two clauses to watch:

1. Whether the right extends to all Investors or only Major Investors. The former creates a queue of small holders to manage in every future round. 2. Whether unused pro rata reallocates among the other Major Investors ("gobble-up" or "over-allotment"). Reallocation is standard and is not offensive, but it means an under-subscribed Major Investor position can end up concentrating with one aggressive fund.

Pro rata rights typically terminate on IPO or an acquisition. Confirm the termination trigger in the drafts.

The term sheet says each Founder and key employee will sign non-competes for [X] years. Two footnotes:

Enforceability varies by state. In California, non-competes are largely unenforceable against employees, and the Federal Trade Commission has attempted to ban them broadly; the enforceability is a moving target.

Even where non-competes are unenforceable, non-solicitation of employees and customers is generally enforceable and is where the real protection sits.

Read this clause not for what it prevents your competitors from doing but for what it prevents you from doing after you leave. Founders sign these and later discover they have restricted their own next move.

Every current and former founder, employee, and consultant must have signed a proprietary information and inventions agreement (PIIA) assigning IP to the company. In diligence, missing PIIAs are the single most common IP defect. Before signing the term sheet, run a list of every person who has ever touched code, product, or brand and confirm each one has an executed PIIA on file. If not, get them signed now — retroactive PIIA signatures after a term sheet arrive in awkward conversations.

Quarterly board meetings, D&O insurance, and indemnification agreements are standard. The clause you should not skip is the requirement that successors assume indemnification obligations in a merger — without it, your board members are personally exposed after an acquisition.

"XYZ% after one year, with remaining vesting monthly over next XYZ months" is describing the standard four-year vest with a one-year cliff. Fill in "25%" and "36." Anything longer than four years total or a cliff longer than one year should be pushed back on.

The ROFR/Co-Sale agreement governs what happens when a founder tries to sell shares. Two rights combine:

Right of First Refusal: the company (first) and the Series A investors (second) can buy the shares before they go to a third party.

Co-Sale (Take-Me-Along): if the founder still sells to the third party, the investors have the right to sell a proportional number of their shares to that third party on the same terms.

The founder-side negotiation is the exemption for permitted transfers — transfers to trusts for estate planning, to family members, or to affiliates should be exempt from ROFR and co-sale. Ask counsel to write the permitted-transfer list into the drafts explicitly.

The block that reads "At the initial Closing, the Board shall consist of 5 members" is the paragraph you will negotiate most personally.

3-2 founder-favorable: 2 founders + 1 investor + 2 independents (or 2 founders + 1 investor + 1 mutually acceptable + 1 to be named). Common at Series A when founders have strong leverage. 2-2-1 balanced: 2 founders + 2 investors + 1 mutually agreed independent. Market default.

Investor-controlled: 1 founder + 2 investors + 2 independents (with investors influencing independents). Rare at Series A; a warning sign.

The independent seat is not a formality. In a founder-CEO transition, in a sale process, and in a down round, the independent director is usually the deciding vote. Do not fill the seat quickly with an acquaintance to move to Closing.

The drag-along lets a defined majority force the remaining stockholders to sell in an acquisition. Watch three parameters:

Who triggers the drag — a majority of the Preferred alone, or a majority of the Preferred and a majority of the Common voting together? Requiring both provides founder protection.

Minimum price floors — is the drag only exercisable if the deal returns at least the liquidation preference, or 1.5x the preference, or has no floor at all?

Excluded obligations — the dragged stockholders should not be required to sign non-competes, provide reps beyond title and authority, or bear indemnification obligations disproportionate to their consideration.

A well-drafted drag protects everyone at exit. A poorly drafted one is used to squeeze minority holders — including founders no longer at the company — in an acquisition they would have voted against.

The Expiration date sets when the term sheet lapses if you have not signed. It is short — usually 3 to 10 business days — and its purpose is to create urgency.

Separately, most Series A term sheets include a no-shop / exclusivity clause of 30–45 days, during which you agree not to solicit or entertain alternative financing offers. The no-shop is the most consequential binding provision in the whole document. Two negotiation levers:

Fiduciary out. The Board should retain the right to respond to unsolicited superior proposals to satisfy its fiduciary duties.

If you sign a no-shop and the deal falls apart in diligence, you have lost a month of process momentum with every other investor who was in your funnel.

These three tail clauses are usually binding. Confidentiality restricts both sides from disclosing the terms; expense reimbursement obligates the Company to cover the lead investor's legal fees up to the cap even if the deal breaks; governing law fixes the forum for any dispute about the term sheet itself.

The final block — "EXECUTED THIS [] DAY OF" — is where the term sheet becomes a document. Two practical notes:

Countersign only after your counsel has read the final version end-to-end.

If your co-founders hold voting rights that matter to the deal (a joint decision on the board seat, for example), have them sign too, or memorialize their consent in a separate acknowledgment.

1. Model the pre-money and post-money cap table both ways (pool in pre, pool in post). 2. Know your walk-away on ownership and board composition. 3. Have counsel on retainer who has closed a comparable Series A this year.

1. Read the header for binding provisions. 2. Circle every number: valuation, price, pool, thresholds, dividend rate, preference multiple. 3. Mark every "so long as at least [X]%" clause and ask what happens at 4%. 4. List the protective provisions and the board composition; those two blocks are what you are actually signing. 5. Push back in writing, then on a call, then in a final markup. Two or three rounds is normal. Ten is a signal.

1. Assume the deal will close in 30 to 45 days. Move due diligence to the top of your calendar. 2. Line up the PIIAs, cap table exhibits, financial statements, and material contract list before drafts arrive. 3. Communicate the no-shop internally so a well-meaning co-founder does not send a "quick update" to another fund.

A term sheet is a Series A in miniature. Read every clause as if it is already the definitive agreement, because in every material respect, it is.